Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
G Missale, … , F Fiaccadori, C Ferrari
G Missale, … , F Fiaccadori, C Ferrari
Published August 1, 1996
Citation Information: J Clin Invest. 1996;98(3):706-714. https://doi.org/10.1172/JCI118842.
View: Text | PDF
Research Article Article has an altmetric score of 12

Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.

  • Text
  • PDF
Abstract

The anti-viral T cell response is believed to play a central role in the pathogenesis of hepatitis C virus infection. Since chronic evolution occurs in > 50% of HCV infections, the sequential analysis of the T cell response from the early clinical stages of disease may contribute to define the features of the T cell response associated with recovery or chronic viral persistence. For this purpose, 21 subjects with acute hepatitis C virus infection were sequentially followed for an average time of 44 wk. Twelve patients normalized transaminase values that remained normal throughout the follow-up period; all but two cleared hepatitis C virus-RNA from serum. The remaining nine patients showed persistent viremia and elevated transaminases. Analysis of the peripheral blood T cell proliferative response to core, E1, E2, NS3, NS4, and NS5 recombinant antigens and synthetic peptides showed that responses to all hepatitis C virus antigens, except E1, were significantly more vigorous and more frequently detectable in patients who normalized transaminase levels than in those who did not. By sequential evaluation of the T cell response, a difference between the two groups of patients was already detectable at the very early stages of acute infection and then maintained throughout the follow-up period. The results suggest that the vigor of the T cell response during the early stages of infection may be a critical determinant of disease resolution and control of infection.

Authors

G Missale, R Bertoni, V Lamonaca, A Valli, M Massari, C Mori, M G Rumi, M Houghton, F Fiaccadori, C Ferrari

×

Total citations by year

Year: 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1994 1988 1961 Total
Citations: 1 1 3 4 32 10 8 8 9 13 15 21 18 16 25 23 25 40 42 35 32 41 36 37 41 28 19 9 2 1 1 596
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2014 (15)

Title and authors Publication Year
DAP12 Deficiency in Liver Allografts Results in Enhanced Donor DC Migration, Augmented Effector T Cell Responses and Abrogation of Transplant Tolerance: DAP12 and Liver Transplant Tolerance
O Yoshida, S Kimura, L Dou, BM Matta, S Yokota, MA Ross, DA Geller, AW Thomson
American Journal of Transplantation 2014
Protective Immunity Against Hepatitis C: Many Shades of Gray
MS Abdel-Hakeem, NH Shoukry
Frontiers in immunology 2014
Immune Responses to HCV and Other Hepatitis Viruses
SH Park, B Rehermann
Immunity 2014
Adaptive immune response during hepatitis C virus infection
JR Larrubia, E Moreno-Cubero, MU Lokhande, S García-Garzón, A Lázaro, J Miquel, C Perna, E Sanz-de-Villalobos
World journal of gastroenterology : WJG 2014
Innate and adaptive immune responses in HCV infections
MH Heim, R Thimme
Journal of Hepatology 2014
Acute Hepatitis C: Management in the Rapidly Evolving World of HCV
SA Sharma, JJ Feld
Current Gastroenterology Reports 2014
Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination
G Ahlén, F Holmström, A Gibbs, M Alheim, L Frelin
Gene Therapy 2014
Induction of Cell-Mediated Immune Responses in Mice by DNA Vaccines That Express Hepatitis C Virus NS3 Mutants Lacking Serine Protease and NTPase/RNA Helicase Activities
SL Ratnoglik, DP Jiang, C Aoki, P Sudarmono, I Shoji, L Deng, H Hotta, G Ahlenstiel
PloS one 2014
Hepatic Immune Regulation and Its Involvement in Viral Hepatitis Infection
PA Knolle, R Thimme
Gastroenterology 2014
Why is it so difficult to develop a hepatitis C virus preventive vaccine?
C Zingaretti, RD Francesco, S Abrignani
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2014
Therapeutic vaccines against hepatitis C virus
J Xue, H Zhu, Z Chen
Infection, Genetics and Evolution 2014
Peptide-pulsed dendritic cells induce the hepatitis C viral epitope-specific responses of naïve human T cells
S Mishra, PT Losikoff, AA Self, F Terry, MT Ardito, R Tassone, WD Martin, AS de Groot, SH Gregory
Vaccine 2014
Immune tolerance in liver disease: HEPATOLOGY, Vol. XX, No. X, 2014 CRISPE
IN Crispe
Hepatology 2014
Reference Module in Biomedical Sciences
DL Sackett, RB Haynes
2014
Latin American Association for the Study of the Liver Recommendations on Treatment of Hepatitis C
N Méndez-Sánchez, R Paraná, H Cheinquer, AA de Mattos, A Gadano, M Silva, MG Pessôa, ML Gomes-Ferraz, A Soza, MC Mendes-Correa, NC Chávez-Tapia, L Dagher, M Padilla, N Hernandez, JF Sánchez-Avila, F Contreras, HS Moraes-Coelho, ER Parise, F Bessone, M Uribe
ANN HEPATOL 2014

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 policy sources
Referenced in 31 patents
Referenced in 1 clinical guideline sources
105 readers on Mendeley
See more details